HDAC-IN-57

• Description:

  HDAC-IN-57 is an orally active inhibitor of histone deacetylases (HDAC), with IC50s of 2.07 nM, 4.71 nM, 2.4 nM and 107 nM for HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-57 can inhibits LSD1, with IC50 of 1.34 μΜ. HDAC-IN-57 induces apoptosis, and has anti-tumor activity[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; HDAC; Histone Demethylase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hdac-in-57.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (C1=CC=C (CNC (C2=CC (C3=CC=C (OC) C=C3) =NC=C2) =O) C=C1) NO

• Molecular Formula:

  C21H19N3O4

• Molecular Weight:

  377.39

• References & Citations:

  [1]Duan Y, et al. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors. Eur J Med Chem. 2023 Jun 5;254:115367.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HDAC1; HDAC2; HDAC6; HDAC8

• CAS Number:

  2716217-79-5